Skip to Content

Cannabis Science: Can Cannabis-Based Drugs Slow the H1N1 "Swine Flu" Pandemic?

SAN FRANCISCO--(BUSINESS WIRE)--Jun 11, 2009 - The World Health Organization declared a swine flu pandemic Thursday, raising its pandemic warning from phase 5 to 6, making swine flu the first global flu epidemic in 41 years. Now that H1N1 "Swine Flu" has been elevated to pandemic status, with reports of outbreaks in Asia, the Middle East and Europe, San Francisco, USA-based Cannabis Science Inc. (OTCBB: CBIS) CEO Steven Kubby urges public health officials around the world to "take medical cannabis seriously."

According to the company, which specializes in cannabis research and development for medical purposes, the world may have at its disposal a means of combating the affects of this deadly disease. Dr. Robert J. Melamede, Director and Chief Science Officer for CSI reports, "Research into use of whole cannabis extracts and multi-cannabinoid compounds has provided the scientific rationale for medical marijuana's efficacy in treating some of the most troubling diseases mankind now faces, including infectious diseases such as the flu and HIV, autoimmune diseases such as ALS (Lou Gehrig's Disease), multiple sclerosis, arthritis, and diabetes, neurological conditions such as Alzheimer's, stroke and brain injury, as well as numerous forms of cancer."

Dr. Melamede went on to say, "The high lethality of some strains of flu can be attributed to the excessive inflammatory response driven by Tumor Necrosis Factor (TNF). Endocannabinoids are nature's way of controlling TNF activity. Phytocannabinoids can mimic the natural endocannabinoids to prevent excessive inflammatory immune responses."

Upon hearing that WHO had elevated the swine flu to pandemic status, CSI's CEO Steve Kubby said, "Governments all over the world ought to seriously consider the advantages of medical cannabis."

On Wednesday, WHO said 74 countries had reported nearly 27,737 cases of swine flu, including 141 deaths. There are over 90 confirmed cases in the United States, with reports of infections in 11 states, and one U.S. fatality, a 23 month old child in Texas. Symptoms include a high fever, body aches, coughing, sore throat and severe respiratory congestion.

Chief Science Officer for CSI Dr. Melamede believes the potential for cannabinoids that naturally prevent excessive inflammatory immune responses is enormous. He stated, "Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we may have a unique solution to the looming threat posed by deadly influenza strains that we believe, if implemented, could save millions of lives."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.



Contact: Cannabis Science Inc.
Steven W. Kubby, 888-889-0888
President & CEO
Brokers and Analysts:
Wall Street International
John Campo, 1-410-236-8200


Posted: June 2009